The estimated Net Worth of Richard A Baron is at least $33.9 mil dollars as of 18 August 2021. Richard Baron owns over 2,343 units of Immunome stock worth over $33,880 and over the last 12 years Richard sold IMNM stock worth over $0.
Sign up
Richard Baron IMNM stock SEC Form 4 insiders trading
Richard has made over 3 trades of the Immunome stock since 2014, according to the Form 4 filled with the SEC. Most recently Richard exercised 2,343 units of IMNM stock worth $26,663 on 18 August 2021.
The largest trade Richard's ever made was exercising 30,000 units of Immunome stock on 2 May 2014 worth over $310,200. On average, Richard trades about 4,391 units every 242 days since 2012. As of 18 August 2021 Richard still owns at least 2,343 units of Immunome stock.
You can see the complete history of Richard Baron stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Richard Baron's mailing address?
Richard's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.
Insiders trading at Immunome
Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime, eMichael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.
What does Immunome do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
What does Immunome's logo look like?
Complete history of Richard Baron stock trades at Zynerba Pharmaceuticals Inc, Globus Medical Inc, eImmunome
Immunome executives and stock owners
Immunome executives and other stock owners filed with the SEC include:
-
Dr. Purnanand Duddu Sarma,
Pres, CEO & Director -
Sandra G. Stoneman Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Michael J. Morin Ph.D.,
Chief Scientist -
Dr. Scott K. Dessain M.D., Ph.D.,
Co-founder & Chairman of the Scientific Advisory Board -
Dr. Dennis H. Giesing,
Chief Devel. Officer -
Matthew K. Robinson Ph.D.,
Sr. VP of R&D -
Corleen M. Roche,
Chief Financial Officer -
Michael Widlitz,
Director -
Michael Lefenfeld,
Director -
Dennis H Giesing,
Chief Development Officer -
Jean Jacques Bienaime,
-
Max Rosett,
EVP, Operations & CFO -
James P Boylan,
-
Philip Tsai,
Chief Technology Officer -
Franklyn G Prendergast,
Director -
Sandra M Swain,
-
I Wistar Iii Morris,
10% owner -
Richard F Fitzgerald,
Chief Financial Officer -
John L Lamattina,
Director -
Michael Rapp,
Director -
Corleen M. Roche,
Chief Financial Officer -
Philip Wagenheim,
-
Richard A Baron,
Director -
Matthew K Robinson,
Chief Technology Officer -
Purnanand D Sarma,
President and CEO -
Clay B Siegall,
President and CEO -
Isaac Barchas,
-
Phil Noland Roberts,
Chief Technology Officer -
Carol Schafer,
-
Kinney Horn,
CHIEF BUSINESS OFFICER -
Jack Higgins,
Chief Scientific Officer -
Robert Lechleider,
Chief Medical Officer -
Bruce Turner,
Chief Strategy Officer